ArticleCureus2024
Prevalence of Anemia in Patients With Rheumatoid Arthritis Presenting at Multi-organization Tertiary Care Hospitals.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An Updated Review on Iron Deficiency Anemia: From Epidemiology to Diagnosis, Etiology, Prevention and Treatment.Journal of blood medicine · 2026Review
- Salidroside: A Potential Drug Candidate to Treat Rheumatoid Arthritis.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) patients often have anemia, which is frequently made worse by the severity of the illness and ongoing inflammation.
objectiveThe objective of this study is to determine the prevalence of anemia among patients with RA presenting at a tertiary care hospital and to explore the relationship between anemia and various clinical parameters of RA. METHODOLOGY: This cross-sectional research evaluated anemia in 330 RA patients in three different hospitals in Pakistan between January and December of 2023. Ages 18 and above, RA diagnosis as defined by the American College of Rheumatology, and permission were the inclusion criteria. Incomplete data or secondary anemic causes were the exclusion criteria. Medical records and interviews were used to gather information on demographics, hemoglobin levels, inflammatory markers, and the severity of RA. SPSS was utilized for the statistical analysis, with significance set at p < 0.05 and Chi-square testing employed to look for relationships between anemia.
resultsIn this study of 330 RA patients, anemia was present in 180 patients (54.55%). The mean hemoglobin level among these patients was 11.41 ± 1.87 g/dL, and the red blood cell count averaged 4.26 ± 0.69 million/µL. Anemic patients had a higher Disease Activity Score (DAS28) with a mean of 5.23 ± 1.42, compared to 4.98 ± 1.35 in the 150 non-anemic patients (45.45%). Elevated C-reactive protein (CRP) levels were observed in 150 (83.33%) of the anemic patients, with a mean CRP of 28.79 ± 12.56 mg/L, while 160 (88.89%) of the anemic patients had an elevated erythrocyte sedimentation rate (ESR), with a mean ESR of 45.17 ± 16.29 mm/hr. Significant associations were found between anemia and longer disease duration (p = 0.042), higher RA severity (p = 0.002), and increased inflammatory markers (p < 0.001).
conclusionAnemia is prevalent among RA patients and is significantly associated with higher disease severity, longer disease duration, and elevated inflammatory markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.